Rozibafusp alfa - AstraZeneca
Alternative Names: AMG 570; Anti-B7RP-1mAb/BAFF; MEDI0700; Rozibafusp alfaLatest Information Update: 06 Nov 2023
At a glance
- Originator Amgen
- Class Anti-inflammatories; Antirheumatics; Bispecific antibodies; Immunoconjugates; Peptide drug conjugates
- Mechanism of Action B cell activating factor inhibitors; B7-related protein 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Systemic lupus erythematosus
- No development reported Rheumatoid arthritis
Most Recent Events
- 27 Apr 2023 Amgen terminates a phase II trial in Systemic lupus erythematosus (In the elderly, In adults) in Argentina, Germany, Canada, Hungary, Australia, Bulgaria, Czech Republic, France, Hong Kong, Italy, Japan, Mexico, Poland, Portugal, South Korea, Russia, Spain and in the US (SC) due to futility (before April 2023) (NCT04058028)
- 15 Mar 2021 Viela Bio has been acquired and merged into Horizon Therapeutics plc
- 05 Nov 2020 Pharmacokinetics, pharmacodynamics, immunogenicity, efficacy and adverse events data presented at 84th American College of Rheumatology and the 55th Association of Rheumatology Health Professionals ((ACR/ARP-2020)